Skip to main content
Top
Published in: Infection 4/2017

01-08-2017 | Original Paper

Pulmonary mucormycosis: clinical features and outcomes

Authors: Erica Lin, Teng Moua, Andrew H. Limper

Published in: Infection | Issue 4/2017

Login to get access

Abstract

Purpose

Mucormycosis encompasses a group of opportunistic fungal infections caused by Zygomycetes, order Mucorales. Mucormycosis can manifest as rhino-orbito-cerebral, pulmonary, gastrointestinal, cutaneous, and disseminated infections. Pulmonary mucormycosis is the second most common presentation. This manuscript characterizes the demographics, clinical presentation, diagnostic procedures, radiologic findings, therapeutic interventions, and outcome in pulmonary mucormycosis.

Methods

We retrospectively reviewed clinical data of 35 patients with pulmonary mucormycosis from 2000 to 2015. Microbiologic diagnosis was based on positive culture from a sterile site or findings on histopathology consistent with mucormycosis. Independent predictors of 28-day mortality were assessed using logistic regression. Survival curves were estimated using Kaplan–Meier method.

Results

There was male predominance with a mean age of 55 ± 15 years. Analysis of predisposing conditions revealed the prevailing presence of malignancy. Sixty-six percent of patients were receiving immunosuppressive agents. Common presenting clinical findings were fever, neutropenia, dyspnea, and cough. Radiologic findings included pleural effusion and nodules. All patients received medical therapy and 43% underwent additional surgical intervention. Twenty eight day mortality was 29% with concurrent bacteremia found as the sole independent predictor. Similar survival from pulmonary mucormycosis was noted over time.

Conclusions

Pulmonary mucormycosis is an opportunistic angioinvasive fungal infection. Physicians must have a high level of suspicion in immunocompromised patients with fever and respiratory symptoms refractory to antibiotics. A low threshold should be had for performing an invasive procedure to gain reliable diagnosis, as early, aggressive medical and surgical interventions are needed for successful treatment.
Literature
1.
go back to reference Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S, Lortholary O, et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med. 2015;36:692–705. doi:10.1055/s-0035-1562896.CrossRefPubMed Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S, Lortholary O, et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med. 2015;36:692–705. doi:10.​1055/​s-0035-1562896.CrossRefPubMed
2.
go back to reference Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57:1044–50.CrossRefPubMed Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57:1044–50.CrossRefPubMed
5.
go back to reference Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20:5–26. doi:10.1111/1469-0691.12371.CrossRefPubMed Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20:5–26. doi:10.​1111/​1469-0691.​12371.CrossRefPubMed
7.
go back to reference Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60–6. doi:10.1086/430710.CrossRefPubMed Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60–6. doi:10.​1086/​430710.CrossRefPubMed
9.
go back to reference Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dellʼAdulto). Br J Haematol. 1997;99:331–6.CrossRefPubMed Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dellʼAdulto). Br J Haematol. 1997;99:331–6.CrossRefPubMed
16.
go back to reference Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–37. doi:10.1016/s1473-3099(16)00071-2.CrossRefPubMed Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–37. doi:10.​1016/​s1473-3099(16)00071-2.CrossRefPubMed
Metadata
Title
Pulmonary mucormycosis: clinical features and outcomes
Authors
Erica Lin
Teng Moua
Andrew H. Limper
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2017
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-017-0991-6

Other articles of this Issue 4/2017

Infection 4/2017 Go to the issue